| SciPort RLP

2021 - 2040

GISAR - REGISTER (#1316)

Dr. Marius,
Prof. Dr. Thomas,
Sergio

2021 - 2026

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)

Prof. Dr. med. Georg

2021 - 2040

MORNING (#1317)

Dr. Marius,
Sergio

2021 - 2027

A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.

Marius,
Dr. med. Alexander

2021 - 2027

Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER®), in patients with recurrent and/or refractory solid tumors

Marius,
Dr. med. Alexander

2021 - 2040

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (#1397)

Dr. Daniel

2021 - 2023

Utilization of the HLA-independent anti-tumor T-cell repertoire for cancer immunotherapy

Univ.-Prof. Dr. Thomas

2021 - 2023

MORE – Molecular Mechanisms of Resilience

Univ.-Prof. Dr. Christoph

2021 - 2025

SFB 1292/Teilprojekt 12

Dr. Michael,
Prof. Dr. Evelyn

2021 - 2040

Sicherheit, Verträglichkeit und Machbarkeit der Behandlung mit GP120-aktivierten regulatorischen T-Zellen (ATreg) frühzeitig nach hämatopoetischer Stammzelltransplantation (HSCT) zur Verringerung der Inzidenz und des Schweregrades der akuten Graft vs. Host Disease (GvHD) (ATreg-001) (#1423)

Dr. Eva Maria

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz